同仁堂國藥（03613.HK）「定志丸【同仁堂】」獲香港中成藥註冊證明書，產品尚未上市

– 1 –

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take
no responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
in reliance upon the whole or any part of the contents of this announcement.


BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
北京同仁堂國藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3613)

VOLUNTARY ANNOUNCEMENT
RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY
CHINESE MEDICINE

This announcement is made by the board of directors (the “Board”) of Beijing Tong Ren Tang
Chinese Medicine Company Limited (the “Company”) on a voluntary basis to inform its
shareholders and potential investors of the latest business development of the Company.

The Board is pleased to announce that the Company recently received the Certificate of Registration
of Proprietary Chinese Medicine (《中成藥註冊證明書》) issued by the Chinese Medicine Council
of Hong Kong (the “Certificate”), allowing “Dingzhi Wan【Tong Ren Tang】” (“定志丸【同仁堂
】”) to be sold in the Hong Kong Special Administrative Region of the People’s Republic of China
(“Hong Kong”). The relevant details are as follows:

I.
Basic Information of the Medicine
Name of the medicine: Dingzhi Wan【Tong Ren Tang】(定志丸【同仁堂】)
Registrant and address: Beijing Tong Ren Tang Chinese Medicine Company Limited at 3 Dai King
Street, Tai Po Industrial Estate, New Territories, Hong Kong
Registration number: HKC-18863
Certificate validity period: Until 29 September 2031

– 2 –


II.
Other Related Information of the Medicine
The functions and main indications of the “Dingzhi Wan【Tong Ren Tang】” are to supplement qi
and nourish the heart, and to calm and settle the mind. It is indicated for patterns of heart qi
instability and deficiency of the five zang organs, manifested by worry, grief and unhappiness,
restlessness of the heart spirit with a tendency to forgetfulness, symptoms mild in the morning and
severe in the evening or recovered in the evening and relapse in the morning, and accompanied by
severe vertigo during episodes. As at the date of this announcement, the Company has cumulatively
invested approximately HK$800,000 (unaudited) in the research and development of “Dingzhi Wan
【Tong Ren Tang】”. This product has not yet been launched for sale in the market.

III.
Impact on the Company and Risk Warning
Upon obtaining the Certificate, “Dingzhi Wan【Tong Ren Tang】” produced by the Company can
be sold in Hong Kong, which is conducive to expanding the product lines of the Company and
beneficial to the market expansion of the Company. The obtaining of the Certificate is not expected
to have any material impact on the production, operation and performance of the Company for the
time being. The sales of pharmaceutical products can be influenced by factors such as changes in the
policy environment, exchange rate fluctuations and market competition in the Hong Kong region.

Shareholders and potential investors should exercise caution when dealing in the securities of
the Company.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Yan Han
Chairman
Hong Kong, 8 October 2026

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:
Independent Non-executive Directors:
Mr. Yan Han (Chairman)
Mr. Tsang Yok Sing, Jasper
Mr. Yue Zheng (Vice Chairman)
Mr. Xu Hong Xi
Mr. Wang Chi
Mr. Chan Ngai Chi


Non-executive Director:

Ms. Feng Li

– 1 –

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不
負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告
全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責
任。

BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
北京同仁堂國藥有限公司
（於香港註冊成立之有限公司）
（股份代號：3613）


自願公告
獲發中成藥註冊證明書

本公告由北京同仁堂國藥有限公司（「本公司」）之董事會（「董事會」）
自願作出，旨在向其股東和潛在投資者提供有關本公司最新業務發展。

董事會欣然宣佈，本公司於近日收到香港中醫藥管理委員會頒發的《中成藥
註冊證明書》（「該證明書」），准許將「定志丸【同仁堂】」在中華人民
共和國香港特別行政區（「香港」）出售，相關情況公告如下：

一、藥品基本狀況
藥品名稱：定志丸【同仁堂】
註冊持有人及地址：北京同仁堂國藥有限公司，香港新界大埔工業邨大景街
3 號
註冊編號：HKC-18863
證明書有效期限：至2031 年9 月29 日止

– 2 –


二、藥品的其他相關情況
「定志丸【同仁堂】」功能主治為益氣養心，安神定志。用於心氣不定，五
臟不足證，症見憂愁，悲傷不樂，心神不定易健忘，朝輕暮劇，或暮愈朝
發，發作時出現強烈的眩暈。截止本公告日，本公司就「定志丸【同仁
堂】」的研發投入累計約港幣8 0 0 , 0 0 0 元（金額未經審計），該產品暫未投
入市場銷售。

三、對本公司的影響及風險提示
取得該證明書後，本公司生產的「定志丸【同仁堂】」可在香港出售，有助
於豐富本公司產品線，有利於其實施市場拓展。該證明書的取得暫不會對本
公司生產經營和業績產生重大影響。藥品銷售容易受到香港地區政策環境變
化、匯率波動、市場競爭等因素的影響。

股東及潛在投資者於買賣本公司證券時務請審慎行事。


承董事會命
北京同仁堂國藥有限公司
主席
嚴晗


香港，2026 年10 月8 日

於本公告日期，董事會成員如下:

執行董事﹕
獨立非執行董事﹕
嚴晗先生（主席）
曾鈺成先生
樂拯先生（副主席）
徐宏喜先生
王馳先生
陳毅馳先生


非執行董事：

馮莉女士